Company Overview
Snapshot
Founded in March 2025 by Doron Friedman and Oron Yacoby - Zeevi, GemCyclo Bio operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on the development of novel orally available cyclic peptides.
Business overview
GemCyclo Bio is an early-stage biopharmaceutical company specializing in the development of innovative new drugs. The company leverages its proprietary Cycloscan technology to design and synthesize a library of orally available cyclic peptides. These peptides are engineered to be highly potent and metabolically stable, targeting validated molecular pathways associated with immune and inflammatory diseases, cancer, and metabolic disorders. GemCyclo Bio's technology aims to combine the benefits of small molecules and larger protein drugs, offering high affinity and selectivity with low immunogenicity and off-target toxicity for the pharmaceutical market.
Log in to access full profile ›Company Intelligence Q&A
- When was GemCyclo Bio founded and by whom?
- GemCyclo Bio was founded in March 2025 by co-founders Doron Friedman and Oron Yacoby - Zeevi.
- What is GemCyclo Bio's primary focus in drug development?
- GemCyclo Bio focuses on developing novel orally available cyclic peptides that target molecular pathways involved in immune and inflammatory diseases, cancer, and metabolic disorders.
- What technology does GemCyclo Bio utilize for its drug discovery?
- GemCyclo Bio utilizes its proprietary Cycloscan technology, licensed from the Hebrew University of Jerusalem, for the rapid design and synthesis of orally available small cyclic peptides.
- What are the key advantages of GemCyclo Bio's cyclic peptides?
- GemCyclo Bio's cyclic peptides are designed to be highly potent and metabolically stable, offering the ease of synthesis and low immunogenicity of small molecules, combined with the high affinity and selectivity of monoclonal antibodies, resulting in low off-target toxicity.
- What is GemCyclo Bio's current product development stage?
- GemCyclo Bio is currently in the R&D product stage, focusing on the development of novel orally available cyclic peptides.